Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
BeiGene, Ltd. | Director | Ordinary Shares | 16.3K | $3.39M | $207.72 | Jun 5, 2024 | Direct |
BeiGene, Ltd. | Director | Share Option (Right to Buy) | 34.2K | Jun 5, 2024 | Direct | ||
ALNYLAM PHARMACEUTICALS, INC. | Director | Stock Option (right to buy) | 5.23K | May 16, 2024 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
BGNE | BeiGene, Ltd. | Jun 5, 2024 | 2 | $0 | 4 | Jun 7, 2024 | Director |
ALNY | ALNYLAM PHARMACEUTICALS, INC. | May 16, 2024 | 1 | $0 | 4 | May 20, 2024 | Director |
BGNE | BeiGene, Ltd. | Feb 29, 2024 | 1 | $0 | 4 | Mar 4, 2024 | Director |
BGNE | BeiGene, Ltd. | Jan 23, 2024 | 0 | $0 | 3 | Jan 23, 2024 | Director |
ALNY | ALNYLAM PHARMACEUTICALS, INC. | May 18, 2023 | 1 | $0 | 4 | May 19, 2023 | Director |
ALNY | ALNYLAM PHARMACEUTICALS, INC. | May 18, 2022 | 1 | $0 | 4 | May 20, 2022 | Director |
ALNY | ALNYLAM PHARMACEUTICALS, INC. | Jul 15, 2021 | 1 | $0 | 4 | Jul 19, 2021 | Director |